Jefferies Financial Group Inc. Invests $749,000 in DENTSPLY SIRONA Inc. $XRAY

Jefferies Financial Group Inc. bought a new stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 59,000 shares of the medical instruments supplier’s stock, valued at approximately $749,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. AQR Capital Management LLC grew its position in DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Norges Bank purchased a new position in shares of DENTSPLY SIRONA in the second quarter worth $39,700,000. Goldman Sachs Group Inc. raised its holdings in shares of DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after buying an additional 2,172,343 shares during the last quarter. Brickwood Asset Management LLP lifted its stake in shares of DENTSPLY SIRONA by 5,515.8% during the third quarter. Brickwood Asset Management LLP now owns 1,524,074 shares of the medical instruments supplier’s stock worth $19,340,000 after buying an additional 1,496,935 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of DENTSPLY SIRONA by 4.1% during the third quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock valued at $279,263,000 after buying an additional 869,566 shares during the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier acquired 27,555 shares of the stock in a transaction on Monday, March 2nd. The shares were acquired at an average price of $14.24 per share, for a total transaction of $392,383.20. Following the transaction, the director owned 27,555 shares in the company, valued at approximately $392,383.20. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James D. Forbes acquired 5,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were purchased at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $124,800. This trade represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 70,000 shares of company stock valued at $956,437. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on XRAY. Robert W. Baird upped their target price on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research note on Wednesday, January 21st. Zacks Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Finally, Mizuho lifted their target price on DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd. Three equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $14.42.

DENTSPLY SIRONA Price Performance

NASDAQ:XRAY opened at $11.80 on Friday. DENTSPLY SIRONA Inc. has a one year low of $9.85 and a one year high of $17.18. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. The firm has a market cap of $2.36 billion, a price-to-earnings ratio of -3.93, a PEG ratio of 1.49 and a beta of 0.97. The firm’s fifty day moving average is $12.72 and its two-hundred day moving average is $12.43.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The company had revenue of $961.00 million for the quarter, compared to analysts’ expectations of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts expect that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.